Search research articles
Contact Us
Filters
Showing results (11-20 of 131) with videos related to
Page
of 14
Sort By:
Expert Opinion on Drug Metabolism & Toxicology
|
July 19, 2021
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature
Alia Fahmy, Ashley M Hopkins, Michael J Sorich, et al.
Pharmaceuticals (Basel, Switzerland)
|
April 30, 2021
Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing
Warit Ruanglertboon, Michael J Sorich, Ashley M Hopkins, et al.
The Oncologist
|
April 5, 2021
Regarding the Article by Rugo et al
Sarah Badaoui, Andrew Rowland, Michael J Sorich, et al.
JNCI Cancer Spectrum
|
February 22, 2023
Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
Ashley M Hopkins, Jessica M Logan, Ganessan Kichenadasse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 26, 2019
Author's Reply
Michael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Breast (Edinburgh, Scotland)
|
June 7, 2019
Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine
Ashley M Hopkins, Andrew Rowland, Jessica M Logan, et al.
Frontiers in Oncology
|
September 12, 2019
Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
Ashley M Hopkins, Andrew Rowland, Ross A McKinnon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 26, 2019
Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC
Michael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Pigment Cell & Melanoma Research
|
February 14, 2019
Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data
Ashley M Hopkins, Madele Van Dyk, Andrew Rowland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 19, 2019
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials
Michael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Page
of 14
Search research articles
Search
Showing results (11-20 of 131) with videos related to
Sort By:
Page
of 14
Expert Opinion on Drug Metabolism & Toxicology
|
July 19, 2021
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature
Alia Fahmy, Ashley M Hopkins, Michael J Sorich, et al.
Pharmaceuticals (Basel, Switzerland)
|
April 30, 2021
Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing
Warit Ruanglertboon, Michael J Sorich, Ashley M Hopkins, et al.
The Oncologist
|
April 5, 2021
Regarding the Article by Rugo et al
Sarah Badaoui, Andrew Rowland, Michael J Sorich, et al.
JNCI Cancer Spectrum
|
February 22, 2023
Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
Ashley M Hopkins, Jessica M Logan, Ganessan Kichenadasse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 26, 2019
Author's Reply
Michael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Breast (Edinburgh, Scotland)
|
June 7, 2019
Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine
Ashley M Hopkins, Andrew Rowland, Jessica M Logan, et al.
Frontiers in Oncology
|
September 12, 2019
Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
Ashley M Hopkins, Andrew Rowland, Ross A McKinnon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 26, 2019
Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC
Michael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Pigment Cell & Melanoma Research
|
February 14, 2019
Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data
Ashley M Hopkins, Madele Van Dyk, Andrew Rowland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 19, 2019
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials
Michael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Page
of 14